Skyhawk Therapeutics, Inc. has administered the first doses of its investigational Huntington’s disease medicine SKY-0515 to patients in the United States as part of the global Phase 2/3 FALCON-HD pivotal programme. Announced on 5 November 2026, the milestone expands clinical testing of the once-daily oral RNA splicing modifier into the US after completion of enrolment in the programme’s Australia and New Zealand study.
The first US participants received treatment at the CenExel Movement Disorder Center in Colorado, while additional American locations, including Beth Israel Deaconess Medical Center, are preparing to begin dosing. Skyhawk reported that more than 50,000 doses of SKY-0515 have now been administered across its clinical programme, involving more than 30 study sites in ten countries.
The expansion follows encouraging Phase 1/2 findings in which Skyhawk reported reductions in mutant huntingtin protein and favourable changes in neurological assessments compared with an externally constructed natural-history control group. However, those findings were generated from a relatively small clinical population, and the longer-term comparison was not a contemporaneous randomised placebo-controlled assessment.
FALCON-HD is designed to address that evidentiary limitation by evaluating SKY-0515 through randomised, double-blind, placebo-controlled studies. Its results will be important in determining whether the biological activity reported in earlier development translates into clinically meaningful effects on Huntington’s disease progression.
Why does US enrolment matter for Skyhawk’s pivotal Huntington’s disease programme?
The FALCON-HD programme consists of two studies identified as SKY-0515-004-ANZ and SKY-0515-004-WW, registered as NCT06873334 and NCT07378644. Both are designed to assess SKY-0515 in adults with Stage 2 or Stage 3 Huntington’s disease, with treatment involving one of three active dose levels or placebo.
The Australia and New Zealand study has completed enrolment with 144 participants. The worldwide study is recruiting across an international network expected to include more than 40 clinical sites, with the beginning of US dosing extending its geographical reach.
The multinational structure is relevant because Huntington’s disease is relatively uncommon, creating recruitment challenges for trials requiring clearly defined genetic, clinical and functional characteristics. Expanding participation across countries can increase access to eligible patients and support the collection of evidence from different clinical environments.
The disease itself is caused by an expanded CAG repeat sequence in the huntingtin gene. It progressively affects movement, cognitive function, behaviour and independence, with symptoms and rates of deterioration varying between patients.
Although medicines are available to manage certain symptoms, no approved treatment has conclusively demonstrated that it slows or stops the underlying progression of Huntington’s disease. This creates substantial unmet need for therapies intended to modify the disease process.
The company’s decision to include patients at defined stages of illness is therefore important. Investigators must balance the need to study people with measurable clinical impairment against the possibility that more advanced neurological damage may be difficult to reverse.
For Skyhawk, US participation also strengthens the programme’s relevance to potential future regulatory discussions. A geographically diverse evidence package could support evaluation of treatment effects across healthcare systems, although regulatory acceptance will ultimately depend on trial quality, endpoint results and the completeness of safety data.
How does SKY-0515 target mutant huntingtin and PMS1 through RNA splicing modification?
SKY-0515 is a small-molecule therapy designed to modify RNA splicing, a process through which cells process precursor RNA before producing proteins. The drug is intended to alter the expression of disease-associated targets rather than directly replacing the defective huntingtin gene.
Its development strategy focuses on two biological mechanisms implicated in Huntington’s disease. The first involves reducing mutant huntingtin protein, which is produced as a consequence of the expanded CAG repeat and contributes to neuronal dysfunction.
The second involves reducing expression of PMS1, a protein involved in DNA mismatch repair processes associated with somatic CAG repeat expansion. Somatic expansion occurs when the repeat sequence becomes longer in certain tissues over time, potentially contributing to disease progression.
Skyhawk considers simultaneous targeting of mutant huntingtin and PMS1 a potentially differentiated approach. In principle, reducing the toxic protein while influencing a mechanism associated with further repeat expansion could affect more than one component of disease biology.
However, the therapeutic relationship between these targets remains under clinical investigation. Lowering mutant huntingtin does not automatically prove that neurons are protected from progressive damage, while reducing PMS1 expression has not yet been established as a clinically effective method of slowing Huntington’s disease.
The approach also raises questions about target selectivity and longer-term safety. RNA splicing is a fundamental cellular process, and medicines designed to alter RNA processing require careful evaluation of their effects on intended and unintended transcripts.
Skyhawk’s proprietary SKYSTAR platform supports the discovery of small molecules designed to influence RNA expression. The potential advantage over some other RNA-targeting approaches is oral administration, which could reduce treatment burden if safety and efficacy are established.
Nevertheless, convenience is secondary to demonstrating meaningful disease modification. The pivotal programme must establish whether the observed molecular effects translate into sustained improvements in outcomes relevant to patients.
What did Skyhawk’s 15-month Phase 1/2 data establish about clinical activity?
In September 2026, Skyhawk reported final 15-month results from its Phase 1/2 clinical study of SKY-0515. The earlier trial involved an initial 12-week randomised, double-blind, placebo-controlled period followed by a blinded extension in which all participants received active treatment.
The extension evaluated daily treatment at 4 mg or 9 mg, with most patients receiving the higher dose. The company reported average mutant huntingtin reductions exceeding 60% and PMS1 messenger RNA reductions exceeding 25% at the 9 mg dose.
These findings provided pharmacodynamic evidence that SKY-0515 was affecting its intended biological targets. However, biomarker reductions cannot independently establish clinical efficacy or demonstrate that neurodegeneration has been slowed.
Skyhawk also reported favourable results on the composite Unified Huntington’s Disease Rating Scale, or cUHDRS, which combines measures of movement, cognition and daily function.
At Month 15, treated participants demonstrated an average improvement of 0.94 points from baseline, while an externally constructed control population showed an estimated decline of 0.65 points. The resulting difference was 1.59 points, with a reported 95% confidence interval of 1.09 to 2.09 and a p-value below 0.001.
The company described favourable differences across the four individual components of the composite measure. These included Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading Test.
However, the Month 15 analysis included only 15 treated participants with available assessments. The limited sample size and reliance on an external natural-history comparison make the result vulnerable to differences in patient selection, disease progression and other potentially influential characteristics.
Skyhawk used overlap-weighted propensity score methods to construct the comparison population from historical datasets, including Enroll-HD, 2CARE and CREST-E. Such methods can improve comparability based on measured variables, but cannot fully eliminate uncertainty arising from unmeasured differences.
The company also explained that declining participant numbers at later time points partly reflected the study design, including differences in exposure duration among participants originally assigned to placebo.
The results are therefore more informative than biomarker evidence alone, but they do not establish the same causal inference as a well-powered randomised comparison maintained throughout the evaluation period.
Why is FALCON-HD’s placebo-controlled design essential for demonstrating disease modification?
Huntington’s disease progression is heterogeneous. Some patients experience relatively gradual decline, while others deteriorate more quickly depending on genetic and clinical characteristics.
This variability complicates the interpretation of small, uncontrolled or externally controlled studies. A treated population may appear to perform better than historical expectations because of differences in baseline disease severity, recruitment patterns or other factors unrelated to the investigational medicine.
Randomisation addresses part of that problem by assigning eligible participants to treatment groups through a controlled process. Blinding and placebo comparison further reduce the influence of expectations and assessment bias.
FALCON-HD’s three active dose levels should also provide information about the relationship between drug exposure, target engagement and clinical outcomes. This could help establish whether stronger biological activity consistently corresponds with measurable treatment benefit.
A clear dose-response relationship may support biological interpretation, although it is not essential for every medicine and must be assessed alongside safety findings. Higher doses may produce greater target engagement but could also increase adverse events.
The trial’s clinical assessments are expected to include measures of motor function, cognitive performance and daily functioning, alongside pharmacodynamic and safety outcomes. Their statistical interpretation will depend on the final prespecified analysis plan and the hierarchy of relevant endpoints.
For a medicine intended to slow disease progression, the duration of follow-up is particularly important. Short-term changes in neurological assessments may reflect symptomatic effects, variability or temporary physiological changes rather than durable modification of the underlying disease.
A convincing result would need to demonstrate a treatment effect that is consistent with clinically meaningful preservation of function over an appropriate observation period.
Longer-term data may also help clarify whether benefit continues after the initial treatment interval and whether patients experience cumulative adverse effects during prolonged dosing.
What do the safety data and 50,000 administered doses mean for clinical confidence?
Skyhawk reported that more than 50,000 doses of SKY-0515 had been administered by the November announcement. This provides an indication of the programme’s cumulative treatment experience, but it should not be confused with the number of individual patients exposed to the medicine.
Because SKY-0515 is administered daily, a relatively small number of patients receiving prolonged treatment can account for many administered doses. The total therefore does not independently establish the size of the safety database or the frequency of uncommon adverse events.
In its September Phase 1/2 update, Skyhawk reported that SKY-0515 had been generally tolerated across the doses studied through 15 months, without treatment-related serious adverse events in the disclosed patient study.
That finding supports continued clinical investigation, but the available population was too small to rule out rare adverse reactions. Longer exposure and larger patient numbers will be important for characterising potential neurological, systemic and off-target effects.
Safety monitoring is particularly relevant because SKY-0515 influences RNA processing and targets biological pathways involved in fundamental cellular functions. Investigators must determine whether the treatment can sustain the desired molecular effects without unacceptable consequences elsewhere.
The pivotal programme includes independent safety oversight and will evaluate adverse events across multiple dose groups. This should provide a more informative assessment of dose-related tolerability than the early clinical programme alone.
Commercial viability will ultimately depend on a treatment regimen that can be maintained over the prolonged periods relevant to a progressive neurological disorder. A medicine that demonstrates biological activity but produces substantial treatment-limiting toxicity may have a narrower clinical role than its mechanism initially suggests.
How could an oral Huntington’s disease therapy alter the competitive treatment landscape?
The Huntington’s disease treatment market includes medicines intended to manage specific symptoms, including involuntary movements. However, these products do not establish modification of the underlying neurodegenerative process.
Several investigational strategies are attempting to address disease biology more directly, including gene-targeting approaches, antisense oligonucleotides and other methods intended to reduce huntingtin production or influence associated pathways.
Different approaches may have distinct advantages and limitations involving treatment administration, tissue distribution, duration of effect and biological selectivity. Cross-trial comparisons are particularly unreliable because disease stage, endpoint selection and assessment periods can differ substantially.
SKY-0515’s oral formulation is commercially interesting because it may offer a more conventional pharmaceutical administration route than therapies requiring specialised delivery procedures. If efficacy and safety are demonstrated, oral treatment could influence the practical requirements for long-term management.
However, its eventual commercial potential cannot be determined from administration convenience or the prevalence of Huntington’s disease alone. Pricing, treatment eligibility, reimbursement and the strength of demonstrated clinical benefit would all influence adoption.
Skyhawk is privately held, and the announcement does not disclose a new financing round, licensing transaction or commercial revenue estimate. The development should therefore be viewed primarily as a clinical execution milestone rather than a direct public-market catalyst.
The US dosing expansion is meaningful because it advances the programme into a broader pivotal testing environment. It does not establish that SKY-0515 is ready for regulatory submission or that approval is likely.
What will determine whether SKY-0515 can become an approved disease-modifying treatment?
The most important next milestone will be the generation of interpretable results from FALCON-HD’s randomised treatment groups. The completed Australia and New Zealand enrolment provides an initial foundation, while recruitment and dosing across the worldwide study will determine the timing and breadth of the subsequent evidence.
Investigators will need to establish whether SKY-0515 produces statistically reliable and clinically meaningful differences against placebo, while maintaining an acceptable safety profile. Results across motor, cognitive and functional assessments will be especially important when evaluating its potential to slow disease progression.
Biomarker evidence can strengthen the mechanistic interpretation if reductions in mutant huntingtin and PMS1 are associated with favourable clinical outcomes. However, those molecular changes cannot replace direct evidence of patient benefit.
For Skyhawk, the November 2026 milestone brings the company closer to answering a question that its Phase 1/2 programme could not resolve. The earlier 1.59-point cUHDRS difference provides an encouraging signal, but its external comparison and small treated population leave uncertainty about the magnitude and reliability of the effect.
FALCON-HD must now determine whether the signal persists under rigorous randomised conditions. That result, rather than the expansion of trial sites or the number of administered doses, will establish whether SKY-0515 has a credible path towards becoming a disease-modifying treatment for Huntington’s disease.
